Home>Topics>>In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin ([[AMRN]] -0.7%) says it submitted a Supplemental New Drug Application to the FDA seeking ...
In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin ([[AMRN]] -0.7%) says it submitted a Supplemental New Drug Application to the FDA seeking ...
In a move to shore up the commercial potential of Vascepa to beyond its patent expiry date of 2030, Amarin ( AMRN -0.7% ) says it submitted a Supplemental New Drug Application to the FDA seeking approval for Chemport, Inc. as an additional Vascepa active pharmaceutical ingredient supplier. The ...
Read the rest of this article on SeekingAlpha.com: SA Currents